Nichi-Iko is set to obtain by 1 April next year all shares in Eisai’s Elmed Eisai value-added generic pharmaceuticals business in Japan, while Nichi-Iko and Elmed Eisai also plan to “integrate their strengths” and co-promote one another’s generic products in the country, as part of a broader, three-part, strategic alliance agreement.
Nichi-Iko is set to obtain by 1 April next year all shares in Eisai’s Elmed Eisai value-added generic pharmaceuticals business in Japan, while Nichi-Iko and Elmed Eisai also plan to “integrate their strengths” and co-promote one another’s generic products in the country, as part of a broader, three-part, strategic alliance agreement.
The Japanese firms will also collaborate to build and promote Eisai’s Total Inclusive Ecosystem ‘patient solutions’ platform, as well as...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
